Nu Skin Enterprises Inc. (NYSE: NUS) today announced fourth quarter and full-year 2025 revenue and earnings within guidance with more than 50% growth in earnings for 2025.

Nu Skin stock is a "Hold" as it trades near 3x 2026 EBITDA but faces secular decline and high execution risk. Here's what investors need to know.

Operator: Good day, and thank you for standing by. Welcome to the Q4 2025 Conference Call. At this time, all participants are ...

Nu Skin Enterprises Inc. (NYSE: NUS), a global beauty and wellness leader, has been ranked the world’s No. 1 company for beauty and wellness device systems by Euromonitor International Ltd. for the ...

Nu Skin's stock has found long-term technical support after a steep decline, with an attractive valuation and improving free cash flow, making it a potential value play. Q1 2025 earnings beat ...

Nu Skin is laying off more employees in the wake of poor earnings performance over the past several quarters, according to a spokesperson for the company. On Thursday, the company posted its ...